The apolipoprotein epsilon4 allele confers additional risk in children with familial hypercholesterolemia

Albert Wiegman1, Eric J G Sijbrands, Jessica Rodenburg

  • 1Emma Children's Hospital/Academic Medical Center, University of Amsterdam, The Netherlands. a.wiegman@amc.uva.nl

Pediatric Research
|March 21, 2003
PubMed

Insights

Familial hypercholesterolemia (FH) shows varied LDL cholesterol in children. The apolipoprotein E4 (apoE4) allele is linked to lower HDL cholesterol in FH children, indicating an added risk.

Area of Science:

  • Genetics
  • Pediatrics
  • Cardiovascular Disease

Background:

  • Children with familial hypercholesterolemia (FH) display significant variability in LDL cholesterol levels.
  • Previous studies included family members, potentially introducing bias; this study focuses on unrelated children and affected sib-pairs to mitigate this.
  • Classical FH diagnosis is based on LDL cholesterol exceeding the 95th percentile for age and gender.

Purpose of the Study:

  • To investigate phenotypic variations in LDL cholesterol among unrelated children with FH and affected sib-pairs.
  • To examine the influence of apolipoprotein (apo) E genotypes, specifically the epsilon4 allele, on lipid profiles in children with FH.
  • To determine if the apoE4 allele contributes to increased cardiovascular risk in pediatric FH.

Main Methods:

  • Phenotypic analysis of 450 unrelated children with FH and 154 affected sib-pairs.
  • Diagnosis of FH based on plasma LDL cholesterol levels above age- and gender-specific 95th percentiles.
  • Analysis of apolipoprotein E genotypes and their association with LDL and HDL cholesterol levels, utilizing an affected sib-pair model for enhanced accuracy.

Main Results:

  • Girls with FH exhibited higher LDL cholesterol levels compared to boys (p = 0.002).
  • HDL cholesterol increased with age in girls (p for trend = 0.005), but not in boys.
  • The epsilon4 allele of apoE was significantly associated with lower HDL cholesterol levels in the affected sib-pair analysis (p = 0.003), explaining 72.4% of the variance.

Conclusions:

  • The epsilon4 allele of apolipoprotein E is associated with reduced HDL cholesterol levels in children with FH.
  • This finding suggests that apoE4 significantly influences HDL cholesterol in pediatric FH.
  • The presence of apoE4 may confer an additional disadvantage and increased cardiovascular risk for children diagnosed with FH.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Lethal Alleles02:41

Lethal Alleles

Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...